VanEck Pharmaceutical ETF
134 hedge funds and large institutions have $411M invested in VanEck Pharmaceutical ETF in 2024 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 38 increasing their positions, 32 reducing their positions, and 11 closing their positions.
227% more call options, than puts
Call options by funds: $1.63M | Put options by funds: $499K
200% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 11
23% more funds holding
Funds holding: 109 → 134 (+25)
19% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 32
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10.43% less ownership
Funds ownership: 86.67% → 76.24% (-10%)
29% less capital inflows, than outflows
Capital inflows: $46.9M | Capital outflows: $66.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
J. Safra Asset Management
New York
|
+$6.09M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.58M |
| 3 |
D.E. Shaw & Co
New York
|
+$3.27M |
| 4 |
Bank Hapoalim BM
Tel Aviv,
Israel
|
+$3.09M |
| 5 |
Jane Street
New York
|
+$3.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$19M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$8.76M |
| 3 |
Verity & Verity
Beaufort,
South Carolina
|
-$7.77M |
| 4 |
Valicenti Advisory Services
Elmira,
New York
|
-$4.96M |
| 5 |
JP Morgan Chase
New York
|
-$4.52M |
PPH Hedge Fund Activity: Q1 2024 in Review
134 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2024, worth a combined $411M — up 7% from $384M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new PPH positions and 11 closed out — a net gain of 22 holders — while 38 added to existing stakes and 32 trimmed.
The largest buyer was J. Safra Asset Management, opening a new position worth an estimated $6.09M. The largest seller was Bank of America, cutting an estimated $19M.
- 134 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2024, up from 109 in Q4 2023.
- Funds reported $411M of VanEck Pharmaceutical ETF stock for Q1 2024, up 7% quarter-over-quarter.
- 33 funds opened new VanEck Pharmaceutical ETF positions in Q1 2024 and 11 closed out, a net change of +22 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q1 2024 was J. Safra Asset Management, an estimated $6.09M added.
- The largest VanEck Pharmaceutical ETF seller in Q1 2024 was Bank of America, an estimated $19M sold.
Based on aggregated 13F filings for Q1 2024.